Pharmacological management of ionizing radiation injuries: current and prospective agents and targeted organ systems
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Introduction: There is a limited array of currently available medicinals that are useful for either the prevention, mitigation or treatment of bodily injuries arising from ionizing radiation exposure.Area covered: In this brief article, the authors review those pharmacologic agents that either are currently being used to counter the injurious effects of radiation exposure, or those that show promise and are currently under development.Expert opinion: Although significant, but limited progress has been made in the development and fielding of safe and effective pharmacotherapeutics for select types of acute radiation-associated injuries, additional effort is needed to broaden the scope of drug development so that overall health risks associated with both short- and long-term injuries in various organ systems can be reduced and effectively managed. There are several promising radiation countermeasures that may gain regulatory approval from the government in the near future for use in clinical settings and in the aftermath of nuclear/radiological exposure contingencies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Filgrastim improves survival in lethally irradiated nonhuman primates
Farese, A. M., Cohen, M. V., Katz, B. P., Smith, C. P., Gibbs, A., Cohen, D. M., & MacVittie, T. J. (2013) · Radiation Research · doi:10.1667/rr3049.1 · Cited by 187
The Eye, Oxidative Damage and Polyunsaturated Fatty Acids
Saccà, S. C., Cutolo, C. A., Ferrari, D., Corazza, P., & Traverso, C. E. (2018) · Nutrients · doi:10.3390/nu10060668 · Cited by 150 · cited 1×
“Dietary ‘polyunsaturated fatty acid’ supplementation has been suggested as a valid therapeutic aid [146].”
BackgroundAnimal models for acute radiation syndrome drug discovery
Singh, V. K., Newman, V. L., Berg, A. N., & MacVittie, T. J. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1023290 · Cited by 139 · cited 1×
“a 60 d observation period is considered more appropriate [14].”
BackgroundSelf-citationPegfilgrastim improves survival of lethally irradiated nonhuman primates
Hankey, K. G., Farese, A. M., Blaauw, E. C., Gibbs, A. M., Smith, C. P., Katz, B. P., Tong, Y., Prado, K. L., & MacVittie, T. J. (2015) · Radiation Research · doi:10.1667/rr13940.1 · Cited by 129 · cited 3×
“Neulasta was approved by the FDA-based NHP study conducted with full supportive care (blood transfusion and use of individualized antibiotics) following Animal Rule [32].”
BackgroundMethodDainiak, N., Gent, R. N., Carr, Z., Schneider, R., Bader, J., Buglova, E., Chao, N., Coleman, C. N., Ganser, A., Gorin, C., et al. (2011) · Disaster Medicine and Public Health Preparedness · doi:10.1001/dmp.2011.68 · Cited by 107
Filgrastim for the treatment of hematopoietic acute radiation syndrome
Farese, A. M., & MacVittie, T. J. (2015) · Drugs of Today · doi:10.1358/dot.2015.51.9.2386730 · Cited by 95
Moroni, M., Ngudiankama, B. F., Christensen, C., Olsen, C. H., Owens, R., Lombardini, E. D., Holt, R. K., & Whitnall, M. H. (2013) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2013.04.041 · Cited by 64 · cited 1×
“experimental animals: mice, canines (beagle), minipigs [19], and”
BackgroundBunin, D. I., Bakke, J., Green, C. E., Javitz, H. S., Fielden, M., & Chang, P. Y. (2020) · International Journal of Radiation Biology · doi:10.1080/09553002.2019.1605465 · Cited by 60 · cited 14×
“A single intraperitoneal (ip) administration of Romiplostim initiated 2 h after irradiation and continued for 3 or 5 days (daily administration, 50 µg/kg) provided 100% survival in C57BL/6J mice exposed to a lethal dose (7 Gy, dose rate 0.9 Gy/min) of Cesium-137 (137Cs) γ-rays [70].”
BackgroundInfluentialWong, K., Chang, P. Y., Fielden, M., Downey, A. M., Bunin, D., Bakke, J., Gahagen, J., Iyer, L., Doshi, S., Wierzbicki, W., et al. (2020) · International Journal of Radiation Biology · doi:10.1080/09553002.2019.1625488 · Cited by 57 · cited 4×
“The most hematologic advantage in respect to platelet and neutrophil was noted when PEGfilgrastim and Romiplostim were dispensed as a combination therapy.”
BackgroundInfluentialGluzman‐Poltorak, Z., Vainstein, V., & Basile, L. A. (2014) · American Journal of Hematology · doi:10.1002/ajh.23770 · Cited by 48 · cited 1×
“It is important to note that G-CSF was not effective when evaluated in the absence of full supportive care (blood products) [43] but GM-CSF was found to be effective without the use of blood products and individualized antibiotics (based on bacterial sensitivity) [42].”
Background
Cited by
Singh, V. K., & Seed, T. M. (2021) · International Journal of Radiation Biology · doi:10.1080/09553002.2021.1969054 · Cited by 88
Self-citationBenderitter, M., Herrera-Reyes, E., Gigov, Y., Souleau, B., Huet, C., Trompier, F., Fagot, T., Grégoire, E., Malfuson, J. V., Konopacki-Potet, J., et al. (2021) · Radiation Research · doi:10.1667/rade-21-00169.1 · Cited by 15
Weiss, M., Nikisher, B., Haran, H., Tefft, K., Adams, J., & Edwards, J. G. (2022) · Life Sciences in Space Research · doi:10.1016/j.lssr.2022.06.006 · Cited by 5
Singh, V. K., & Seed, T. M. (2022) · Life Sciences in Space Research · doi:10.1016/j.lssr.2022.09.004 · Cited by 3
Self-citation
Metadata
- Authors
- Singh, V. K., & Seed, T. M.
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa UK Limited
- Published
- 2020-01-11
- Volume
- 21
- Issue
- 3
- Pages
- 317-337
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- OpenAlex
- W2998768115
- Cited by
- 125
- References
- 11
- FWCI
- 6.39
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacological management of ionizing radiation injuries: current and prospective agents and targeted organ systems. https://app.cochat.ai/papers/10.1080/14656566.2019.1702968
- The paper
- Singh, V. K., & Seed, T. M. (2020). Pharmacological management of ionizing radiation injuries: current and prospective agents and targeted organ systems. Expert Opinion on Pharmacotherapy. https://doi.org/10.1080/14656566.2019.1702968
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.